Table 1.

Summary of cytokeratin staining by mutation status, with ORs for staining positivity for BRCA1 and BRCA2 carriers compared with controls

MarkerLevelControl
BRCA1
BRCA2
n (%)n (%)OR (95% CI)Pn (%)OR (95% CI)P
CK14Neg150 (88.2)95 (39.4)1.066 (75.9)1.0
Pos20 (11.8)146 (60.6)12.47 (5.52-28.21)<0.000121 (24.1)2.25 (0.89-5.67)0.085
CK14, % staining<1%150 (88.8)96 (39.8)1.066 (75.9)
1-10%14 (8.3)68 (28.2)8.08 (3.25-20.06)12 (13.8)
11-50%3 (1.8)41 (17.0)47.8 (6.15-371.0)4 (4.6)
51-100%2 (1.2)36 (14.9)23.5 (3.00-185.0)0.00015 (5.7)
CK14, intensityNone150 (88.2)95 (39.4)1.066 (75.9)
+17 (10.0)96 (39.8)9.32 (3.89-22.31)14 (16.1)
++1 (0.6)10 (4.1)32.58 (7.43-143)<0.00012 (2.3)
+++2 (1.2)40 (16.6)5 (5.7)
CK5/6Neg155 (93.4)86 (42.4)1.044 (84.6)
Pos11 (6.6)117 (57.6)22.27 (7.78-63.75)<0.00018 (15.4)2.73 (0.77-9.75)
CK5/6, % staining<1%155 (93.4)87 (42.9)1.044 (84.6)
1-10%8 (4.8)51 (25.1)11.07 (3.65-33.53)<0.00015 (9.6)
11-50%3 (1.8)37 (18.2)85.7 (12.66-580)<0.00010 (0.0)
51-100%0 (0.0)28 (13.8)3 (5.8)
CK5/6, intensityNone155 (93.4)86 (42.4)1.044 (84.6)
+9 (5.4)83 (40.9)22.24 (8.11-61.0)7 (13.5)
++2 (1.2)26 (12.8)22.36 (4.77-104.7)<0.00010 (0.0)
+++0 (0.0)8 (3.9)1 (1.9)
CK17Neg179 (90.4)99 (46.7)1.039 (92.9)1.0
Pos19 (9.6)113 (53.3)7.1 (3.29-15.29)<0.00013 (7.1)0.56 (0.1-3.16)
OsteoNeg161 (81.3)121 (56.8)1.032 (76.2)1.0
Pos37 (18.7)92 (43.2)4.09 (2.0-8.39)0.000110 (23.8)1.61 (0.44-5.91)
EGFRNeg85 (78.7)56 (32.7)1.033 (91.7)1.0
Pos23 (21.3)115 (67.3)6.88 (2.88-16.45)<0.00013 (8.3)0.27 (0.04-1.62)
  • Abbreviations: CK, cytokeratin; Osteo, osteonectin; Neg, negative; Pos, positive.